These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32015437)

  • 1. RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering.
    Smargon AA; Shi YJ; Yeo GW
    Nat Cell Biol; 2020 Feb; 22(2):143-150. PubMed ID: 32015437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas guides the future of genetic engineering.
    Knott GJ; Doudna JA
    Science; 2018 Aug; 361(6405):866-869. PubMed ID: 30166482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR: development of a technology and its applications.
    Derry WB
    FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas Systems in Streptococci.
    Gong T; Lu M; Zhou X; Zhang A; Tang B; Chen J; Jing M; Li Y
    Curr Issues Mol Biol; 2019; 32():1-38. PubMed ID: 31166168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Industrial Biotechnology Using CRISPR-Cas Systems.
    Donohoue PD; Barrangou R; May AP
    Trends Biotechnol; 2018 Feb; 36(2):134-146. PubMed ID: 28778606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR technologies and the search for the PAM-free nuclease.
    Collias D; Beisel CL
    Nat Commun; 2021 Jan; 12(1):555. PubMed ID: 33483498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling and enhancing CRISPR systems.
    Shivram H; Cress BF; Knott GJ; Doudna JA
    Nat Chem Biol; 2021 Jan; 17(1):10-19. PubMed ID: 33328654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of Microbial Diversity to Discover Novel Molecular Technologies.
    Zhang F
    Keio J Med; 2019; 68(1):26. PubMed ID: 30905885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR as a Diagnostic Tool.
    Kim S; Ji S; Koh HR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR: History and perspectives to the future.
    Kozovska Z; Rajcaniova S; Munteanu P; Dzacovska S; Demkova L
    Biomed Pharmacother; 2021 Sep; 141():111917. PubMed ID: 34328110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inconclusive studies on possible CRISPR-Cas off-targets should moderate expectations about enzymes that have evolved to be non-specific.
    Chakraborty S
    J Biosci; 2018 Jun; 43(2):225-228. PubMed ID: 29872009
    [No Abstract]   [Full Text] [Related]  

  • 17. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the scope of plant genome engineering with Cas12a orthologs and highly multiplexable editing systems.
    Zhang Y; Ren Q; Tang X; Liu S; Malzahn AA; Zhou J; Wang J; Yin D; Pan C; Yuan M; Huang L; Yang H; Zhao Y; Fang Q; Zheng X; Tian L; Cheng Y; Le Y; McCoy B; Franklin L; Selengut JD; Mount SM; Que Q; Zhang Y; Qi Y
    Nat Commun; 2021 Mar; 12(1):1944. PubMed ID: 33782402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR RNA-guided autonomous delivery of Cas9.
    Wilkinson RA; Martin C; Nemudryi AA; Wiedenheft B
    Nat Struct Mol Biol; 2019 Jan; 26(1):14-24. PubMed ID: 30598555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.